The observation that PLK1 is overexpressed in tumor cells [13–17], including non-Hodgkin's lymphoma [18], where it is associated with a poor prognosis [16, 17], but not in normal cells [19], makes it a logical target for therapeutic intervention. The gene discussed is PLK1; the disease is neoplasm.